← Back to 9 Meters Biopharma Stock
9 Meters Biopharma (NMTRQ) News
https://www.investing.com/news/assorted/9-meters-biopharma-files-for-bankruptcy-ceases-operations-432SI-3127861
Drug developer 9 Meters Biopharma and its units have filed for Chapter 11 bankruptcy protection, it said in a regulatory filing on Tuesday, sending its shares tumbling 66% in premarket trading.
9 Meters Biopharma (NMTR) lost ~16% on Tuesday after announcing the immediate resignation of its President and Chief Executive Officer John Temperato. Read more here.
9 Meters Biopharma press release (NMTR): Q1 GAAP EPS of -$1.02 misses by $0.24.As of March 31, 2022, the Company''s unrestricted cash and cash equivalents totaled approximately…
9 Meters Biopharma (NMTR) expects to file an application to the FDA in H2 2023 for starting a trial of its obesity drug NM-136. Read more here
9 Meters Biopharma press release (NMTR): Q4 GAAP EPS of -$0.92 misses by $0.12.As of December 31, 2022, the Company had total cash and cash equivalents of approximately $29.7…
RALEIGH, NC / ACCESSWIRE / March 15, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today the closing of its previously announced registered direct offering of 3,125,000 shares of the Company''s common stock (or common stock equivalents) and warrants to purchase 6,250,000 shares of common stock at a combined purchase price of $1.60 per share of common stock (or common stock equivalent) and accompanying warrant priced at-the-market under Nasdaq rules. The warrants have an exercise price of $1.35 per share, are immediately exercisable, and expire three and one-half years following the date of issuance. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. The gross proceeds to 9 Meters from the public offering were approximately $5 million. The Company intends to use the net proceeds of this offering, together with other available funds, to support the clinical development of vurolenatide for the treatment of short bowel syndrome, to fund the development of the Company''s other pipeline programs, as well as for working capital and general corporate purposes.
GitLab GTLB -30% on Q4 earnings release.Cingulate (CING) -11%.9 Meters Biopharma NMTR -9% after proposes to raise $5M in stock offering.BigBear.ai BBAI -9% on Q4 earnings…
RALEIGH, NC / ACCESSWIRE / March 7, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced that John Temperato, President and Chief Executive Officer of 9 Meters, is scheduled to present at the Oppenheimer 33rd Annual Healthcare Conference. Oppenheimer 33 rd Annual Healthcare Conference Date: Monday, March 13, 2023 Time: 3:20 PM ET Webcast link The presentation will highlight the Company's pipeline, with a focus on vurolenatide, its long-acting GLP-1 agonist in Phase 3 development for short bowel syndrome, as well as upcoming milestones.
A share of 9 Meters Biopharma Inc. (NASDAQ:NMTR) closed at $2.11 per share on Friday, up from $2.06 day before. While 9 Meters Biopharma Inc. has overperformed by 2.68%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, NMTR fell by -84.49%, with highs and lows ranging […]